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Abstract As a result of recent breakthroughs in cancer
immunotherapies, unprecedented and durable remission,
and even cure, has been reported in some patients. Im-
portantly, this progress has been achieved, not by the in-
duction of immunity, but by the delivery of immunity in
the form of engineered antibodies (eAbs) or effector T
cells. However, these single-target technologies have failed
to result in a therapeutic effect in some patients, and evi-
dence suggests that further advances depend on an effec-
tive strategy for coping with cancer heterogeneity and
dynamics. A synthetic immunity (SI) strategy is proposed
to achieve this goal. The fundamental basis of SI involves
the generation of a panel of eAbs and antibody-retargeted
CTLs designed to destroy all cell lineages of a cancer with
high specificity. This goal can be achieved only when the
composition of the eAbs is determined using a systematic
approach, i.e., selecting the antigens targeted by the eAbs
based on an epitope-tree illustrating the clonal antigen ar-
chitecture of the cancer. Integration of technologies that
increase the epitope breadth, eAb affinity and T cell
activity will further enhance the efficacy of SI. Using DNA
vectors to express the eAbs will be a safe, effective and
affordable solution.
Keywords Cancer immunotherapy  Synthetic
immunity  Non-viral vector  Engineered antibody 
Bispecific antibody  Retargeting T cell
1 Introduction
The pathogenesis of cancer is a multiple-step process [1–
4], taking from 10 to 20 years or more for the manifesta-
tion of cancer from a single initiated cell. The host immune
system holds the cancer at the stealthy ‘‘elimination and
equilibrium’’ phases for 90 % of its development history,
with outgrowth being the consequence of ‘‘escape’’ from
immune surveillance [1, 2]. Both the innate and adaptive
immune systems participate in the battle against the cancer
development, although adaptive immunity plays the major
role [1, 5]. Human adaptive immunity comprises B cell and
T cell responses, the function of which is to recognize and
kill the ‘‘non-self’’ invaders. In addition to microbes, can-
cer cells can also be recognized as ‘‘non-self’’ and
eliminated by the host immune system [1]. The cancer-
specific antigens that induce such immune responses can be
divided into the following five classes: (1) mutated anti-
gens that are produced by mutated genes such as EGFRvIII
[6] and the p53 and Ras families [7]; (2) cancer–germ line
antigens, also known as cancer–testis antigens, which are
expressed in germ cells with immune privilege and ex-
pressed in certain cancers, such as the GADE, CTAG, SSX
and MAGE gene families [7]; (3) viral proteins, expressed
by viruses such as hepatitis B virus (HBV), Epstein–Barr
virus (EBV) and human papilloma virus (HPV); (4) over-
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expressed proteins that are expressed at very high levels in
some cancers but at very low levels in some normal tissues,
including EpCAM- and prostate-specific antigen (PSA);
and (5) differentiation antigens, which are expressed by
particular cell types, such as GP100 and melan-A in me-
lanoma [7].
Three factors have been attributed to the transition of
cancer development from the ‘‘equilibrium’’ to the
‘‘escape’’ phase [1]: (1) the accumulation of mutations that
cause the cancer to grow more aggressively and become
‘‘invisible’’ to the host immune system [1, 5]; (2) the de-
velopment of host immune tolerance that leads T cells to
become unresponsive and unable to contain the cancer; and
(3) the development of a cancer suppressive microenvi-
ronment that results in immune effector cell dysfunction [1,
8, 9]. Recently, breakthroughs in anticancer im-
munotherapy have been achieved by direct delivery of
immunity, i.e., the administration of engineered T cells
[such as tumor infiltrating lymphocytes (TILs) and chi-
meric antigen receptor modified T cells (CARTs)] and
antibodies (eAbs) [such as bispecific antibody (BsAb) ca-
pable of retargeting T cells and immune checkpoint
blocking antibodies (Ab) for unleashing T cells] [10–14].
Unprecedented success has been achieved using this ap-
proach in terms of the proportion of the treated patients
experiencing complete remission, or even cure, indicating
that this strategy overcomes the barrier of immune sup-
pression, at least partially. However, these successes are
limited, with a substantial proportion of the treated patients
experiencing only transient remission or complete failure
to respond. The perspectives presented here summarize
these promising technologies, define the mechanisms that
form the bottleneck to these immunotherapeutic advances
and propose the synthetic immunity (SI) strategy as a
systematic approach to further overcome the cancer-related
suppression mechanism and bring cancer immunotherapy
to a new level of efficacy.
2 Recent breakthroughs in cancer immunotherapy
Recently, encouraging progress has been reported in anti-
cancer clinical trials of eAbs and T cell engineering tech-
nologies. As the foundation of the SI strategy, these
technologies are summarized briefly as follows:
2.1 Monoclonal antibodies (mAbs)
mAbs have been used for treating cancers for decades
because they are able to bind the targets on cancer cells
with high specificity and affinity [15, 16]. In addition to
inducing antibody-dependent cell-mediated cytotoxicity
(ADCC) [17], mAbs can also be used to destroy cancer
cells through the delivery of conjugated toxins and iso-
topes. The application of traditional anticancer antibodies
has been well summarized in recent reviews and is there-
fore not described here [15, 16]. Recently, a class of so-
called immune checkpoint blockades, including the anti-
programmed death protein-1 (PD-1) and anti-cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), has demon-
strated promising results in clinical trials of the treatment
of multiple solid cancers, such as melanomas, prostate
cancers and even the extremely aggressive non-small cell
lung cancers [14, 18]. PD-1 and CTLA-4, which are ex-
pressed by immune cells such as T cells, dendritic cells
(DC), nature killer (NK) cells, negatively regulate T cell
activation by stimulating the intracellular signaling path-
ways leading to cellular inactivation upon binding to their
ligands PD-LI/2 and B7, respectively. Several cancers ex-
press these ligands as an escape mechanism to inactivate
CTLs and avoid destruction. Monoclonal antibodies
(mAbs) that block these ligand–receptor interactions
overcome this escape mechanism and retain the capacity of
CTLs to destroy the cancer cells. These results confirm the
presence of multiple inactivated anticancer CTL clones in
patients’ tumors, which could be reactivated to perform the
function of immune surveillance and herald a new era in
antibody-mediated anticancer immunotherapy. Many clin-
ical trials are being conducted to determine the efficacy of
this approach in other cancers [14, 18]. These mAbs have
demonstrated moderate off-target effects and are under-
going optimization [7, 19]. To date, the US FDA has ap-
proved the use of an antibody against CTLA-4 for the
treatment of melanoma [20].
2.2 Tumor infiltrating lymphocytes (TILs)
TILs are collected from surgical tumor samples, amplified
in vitro and reinfused into the patient. In a recent study, a
group of 93 patients with metastatic melanomas were
treated with this technique; 50 % responded to the treat-
ment, and 20 % survived for 64–109 months [11, 21].
More recently, the same group of researchers reported that
a woman with cholangiosarcoma responded well to the
infusion of TILs containing a high proportion of mutated
ERBB21P-specific CD4?CTLs [22]. This observation
suggests that TILs are also effective for the treatment of
solid cancers of epithelial cell origin, which account for
approximately 90 % cancer deaths in USA. These results
further confirm that cancer-specific CTL clones exist
in vivo and are able to destroy the cancer cells following
in vitro expansion and reinfusion into the patients. Because
TILs are autologous T cells, this approach is associated
with few side effects. However, to prolong the persistence
of the TILs in vivo, patients have to undergo a ‘‘preparative
lymphodepletion’’ procedure, consisting of chemotherapy
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alone or in combination with whole-body irradiation prior
to TIL infusion, and the administration of the T cell growth
factor IL-2 treatment after cell delivery. These results are
in accordance with histological studies demonstrating that
the presence of TILs in cancer tissues is associated with
improved survival in patients with prostate, breast, col-
orectal and ovarian cancer or melanoma [11]. Clinically,
however, although TILs are highly effective in treating
patients with melanomas, this approach achieves only
limited efficacy in patients with renal cancers and is inef-
fective for the treatment of other tumors [21, 23]. The
mechanism underlying these disparate responses is not
known at present. More clinical trials are in progress in an
attempt to expand these early successes [21] although the
technique used to scale-up TIL production remains to be
optimized.
2.3 Chimeric antigen receptor modified T cells
(CARTs)
CARTs are generated by replacing the extracellular portion
of the TCR of the CTL with a single-chain antibody
(mAb); therefore, the chimeric antigen receptor is also
called a TCR-like antibody [24]. This changes the T cell
specificity such that an Ab–antigen interaction occurs in-
stead of the usual receptor–ligand (TCR-MHC-peptide)
interaction, leading to enhanced target killing activity.
Currently, CARTs are generated by transducing T cells
with lentiviral, retroviral or transposon vectors expressing
the chimeric antigen receptor. The transduced T cells are
then expanded in vitro before being infused back into the
patient [25]. Compared with the earlier technology, such as
the recombinant TCR (rTCR), which is a natural TCR
mimic, CARTs have many advantages, including the fol-
lowing: (1) CARTs can be more easily produced using
well-established Ab engineering technology; (2) CARTs
are also able to target he unconventional B cell epitopes
and kill tumor cells in both MHC-dependent and inde-
pendent manners, while MHC presentation is required by
rTCRs; (3) CARTs have a much higher binding affinity and
hence higher therapeutic efficacy than CTLs and rTCRs
[26]; (4) the third generation CARTs, which are con-
structed with elements capable of generating strong intra-
cellular signals, exhibit greatly enhanced cancer cell killing
efficiency [27, 28]. In addition to hematological malig-
nancies, CARTs are also effective in melanoma and syn-
ovial cell sarcoma [21]. The first case of successful cancer
treatment using this technology was reported in a patient
with advanced B lymphoma treated with a CART targeting
CD19. The patient underwent a partial remission that lasted
for 32 weeks after the CART infusion [29]. The efficacy of
CARTs is further confirmed by their ability to eradicate
kilograms of leukemia in a few weeks in patients whose
cancers were refractory to chemotherapy [30]. In a recent
report, CART therapy resulted in complete remission in 55
patients out of a group of 75 with B cell malignancies [31].
Multiple CART clinical trials are being conducted for the
treatment of sarcoma, kidney and other epithelial cancers
[21]. However, CARTs can induce severe side effects, in-
cluding the massive overproduction of cytokines known as
‘‘cytokine storm’’, which can be fetal and a related death
was reported in an earlier trial [32]. CART technology is
also limited by high cost and difficulty in scaling-up pro-
duction. To overcome these obstacles, an RNA-based
CART has been developed recently, in which mRNA is
used to replace the viral vector to generate shorter-lived
CART populations. This modified CART technology,
which has reduced off-target toxicity, reduced production
costs and improved the ease of scale-up, is currently being
tested in several clinical centers [25, 32].
2.4 Bispecific antibodies (BsAbs)
BsAbs, also known as bispecific T cell engagers (BiTEs)
[10, 33], are a class of antibodies capable of binding two
antigens simultaneously. They were made initially by
chemically mediated cross-linking of two antibodies [34]
or quadroma technology and are currently generated using
antibody-engineering technology [35, 36]. When used in
cancer immunotherapy, BsAbs function as TCRs, i.e.,
forming a synapse between the T cell and cancer cell to
initiate killing of the target [37]. BsAbs are highly effective
in anticancer therapy. The typical BsAb blinatumomab,
which binds to both CD3 on T cells and CD19 on B cells,
was shown to result in regression of B cell malignancies in
all seven patients treated at a daily dose as low as 90 lg (in
a 60-kg human) [10]. However, it is associated with two
drawbacks: (1) With a half-life of only 2–3 h in circulation,
a minipump is required for continuous drug delivery to
maintain an effective concentration throughout the course
of the treatment; (2) it kills both normal B cells and their
precursors, although the loss of normal B cells is not lethal
and its consequences are manageable. Furthermore, this
problem can be avoided by using tumor-specific targets
[38]. The first EU FDA-approved BsAb, catumaxomab, has
demonstrated excellent therapeutic results in clinical trials
for the treatment of malignant ascites [39]. Catumaxomab
is a trifunctional BsAb; in addition to binding the T cell
CD3 and the tumor epithelial cell adhesion molecule
EpCAM, it includes an Fc region capable of recruiting
DCs, NKs and macrophages expressing FccR receptors. It
has been demonstrated that this achieves a coordination of
adaptive and innate immune elements, and consequently,
the induction of the long-term memory immune responses
desired for cancer immunotherapy [40]. Catumaxomab is
effective in treating ascites resulting from almost all
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abdominal cancers overexpressing EpCAM, including
gastric, pancreatic and ovarian cancers [41]. Compared to
the TIL and CART technologies, BsAbs have many other
advantages that will be summarized later.
In summary, these successes represent breakthroughs in
the long history of human anticancer strategies. Impor-
tantly, these successes are achieved not by the induction of
immunity, but by the delivery of immunity in the form of
engineered Abs or T cells that mediate the therapeutic ef-
fects. In contrast, only a small fraction of the numerous
cancer therapeutic vaccine clinical trials have demonstrated
objectively determined effects [11]. These observations
suggest that there are significant obstacles to the generation
of effective vaccine responses in cancer patients and that
the delivery of immunity is the most effective way to
overcome cancer-related immune suppression. However,
the successes to date are far from satisfactory, with re-
sponses seen only in a subset of patients, and many expe-
riencing only an incomplete and transient regression or a
complete failure to respond [10, 11, 14, 18, 21, 29]. In
order to break down the bottleneck and make further pro-
gress in the field of cancer immunotherapy, it is important
to understand the mechanisms underlying the break-
throughs and remaining obstacles.
3 Cancer heterogeneity at the center of immune escape
It is suggested that patients have demonstrated different
responses to the treatments because of the heterogeneity of
TIL populations comprising cells in different differen-
tiation states, which are inactivated through different
mechanisms; therefore, it is likely that different strategies
will be required to restore their cellular function [8]. This
hypothesis explains the incomplete response to treatment
with in vitro expanded TILs and the immune checkpoint
inhibitors that work by relieving the suppression of TILs,
but not the success of the CART and BsAb technologies.
CARTs are made by recombinant vector-mediated ex-
pression of target molecules in T cells derived from pe-
ripheral blood mononuclear cells (PBMC), while BsAbs
work by conferring in vivo CD3-positive T cells with
cancer-specific cytolytic (CTL) function. Thus, both T cell
types are derived from active T cells capable of killing
cancer cells without the need for an activation step. Given
that all four treatment strategies target only one cancer
antigen, it is reasonable to hypothesize that the genetic
heterogeneity of cancers is the major mechanism underly-
ing the incomplete responses and is also responsible for the
failure of therapeutic vaccination.
Cancer and virus heterogeneity is one of the major
mechanisms underlying their escape and treatment failure.
With almost no exceptions, an HIV infection comprises
multiple clones [42, 43], and a cancer, although derived
from one single cell, comprises multiple cell lineages that
continue to evolve [2, 3, 44–47]. Actually, a cancer is a
micro-ecosystem subject to selection pressure and evolu-
tionary processes similar to those that shape ecosystems in
nature as described by Darwin [3, 4, 48, 49]. In an unfa-
vorable environment, many cells die and only the fittest
survive and thrive. Selection pressure comprises many
factors [50, 51], including hypoxia due to poor circulation
resulting from the rapid growth of cancers, and acidity
resulting from aerobic glycolysis—the so-called Warburg
effect [52, 53]—that occurs in almost all solid cancers
(Supporting Information Box 1). Immune editing is another
important selection factor [1, 5], where the host immune
surveillance eliminates the emerging cancer cells with
strong antigenicity, leaving only weakly antigenic cells that
escape detection and elimination. Therapeutic drugs are
also powerful selection factors [3]; most of the current
targeting treatments, including small molecules (e.g., ty-
rosine kinase inhibitors) [54–57], antibodies [15, 16] and
engineered T cells [10, 12, 22, 58], target only one cell
lineage [54, 55]. Consequently, only partial or transient
remission is achieved, and although some treatments do
result in a longer-term remission, relapse occurs eventually
[48, 57, 59]. One such example is the interesting obser-
vation that in multiple cancer patients treated with anti-PD-
L1, the preexisting lesions regressed while new lesions
emerged [60]. The fundamental mechanism underlying
these phenomena is clear—only the targeted lineage is
destroyed, while the untargeted lineages survive and grow
continuously. Consequently, a cancer can evolve before
and after treatment, and metastatic cancers can differ from
the parental tumor [2, 44, 48, 57]. This hypothesis is
schematically illustrated in Fig. 1a. The same mechanism
may be responsible for the failure of therapeutic vaccina-
tion. Conceivably, a therapeutic vaccine will stimulate
immune responses that kill the targeted cancer cell lin-
eages, but not the untargeted lineages, which will continue
to thrive. However, the reasons for the failure of
therapeutic vaccination may be much more complicated.
This hypothesis is supported by a recent report that a
vaccine designed to protect against HIV infection resulted
in an increase in the risk of HIV infection, with some
vaccine-induced antibodies promoting the infection [61–
63]. Other studies also revealed unexpected immune re-
sponses targeting particular subsets of DCs that induced
immune tolerance [64], or inhibition of tumor-specific
CTLs [65, 66].
It has been well documented that genetic variations, in-
cluding single-nucleotide polymorphisms (SNP), insertion,
deletion and inversion, play important roles in cancer ini-
tiation, promotion, progression, metastasis and response to
anticancer therapies. A large number of genes are involved,
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including oncogenes, tumor suppressor genes and genes in-
volved in DNA repair, drug metabolism, J-V-D recombina-
tion and signal transduction pathways. For example, the
efficacy of the antibody trastuzumab (Herceptin) in breast
cancer treatment is greatly influenced by the FccRIIIA-158
polymorphism [65]. These will not be described in detail
because this class of genomic alterations occurs before
cancer initiation and is not within the scope of present review
of cancer heterogeneity and immunotherapy.
4 Synthetic immunity (SI) for further breakthroughs
It is apparent that only technologies capable of coping ef-
fectively with the heterogeneity and dynamics of cancers
will lead to further breakthroughs. Accordingly, a SI
strategy is proposed to achieve this goal. The principle of
SI involves the generation of a panel of engineered anti-
bodies (eAbs), mAbs and BsAbs, aiming at killing all the
cell lineages of a cancer with no possibility of escape.
BsAbs confer T cells with cancer-specific CTL function
[10], and mAbs disable virus infections or induce the death
of cancer and virus-infected cells through Ab-induced
ADCC [15, 16]. To ensure that none of the cell lineages
escape, the eAbs are designed under the guidance of an
epitope-tree illustrating the clonal antigen architecture of
the cancer; this issue will be addressed later.
The power of SI will be enhanced further by a series of
technologies including (1) optimization of the binding
affinity and avidity of the eAbs, for either effector or
cancer targets, to enhance functional efficiency compared
with that of the natural Abs or TCRs [21]; (2) using
technologies such as vaccination to increase the number
of BsAb-retargetable T cells and hence the cancer-specific
CTLs with predetermined efficiency (e.g., EBV-specific
CTLs [67] or cytomegalovirus (CMV)-specific CTLs)
[68]; and (3) using gene and cell engineering technologies
to tap into the unmined riches of T cell epitopes to ex-
pand the immunotherapeutic repertoire of the SI. This
possibility is illustrated by a recent anti-HIV vaccination
study [42], in which monkeys were vaccinated using a
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Fig. 1 The synthetic immunity strategy. (a) A cancer comprises multiple cell lineages and mutation-derived new lineages continually emerge.
Treatments, including small molecule drugs, antibodies and T cell-based immunotherapies and therapeutic vaccines, destroy only the targeted
cell lineage(s) while allowing the untargeted cells to continue growing, and rendering these treatments ineffective [44, 55]. Red circles indicate
the drug-targeted cell lineage; blue and black circles, the untargeted lineages; green circles, newly emerged cell lineages. (b) A minicircle can be
used to produce mAb or BsAb; the mAb can kill cancer cells by inducing antibody-dependent cellular cytotoxicity (ADCC), while the BsAb can
bind cellular surface antigens of the T cell and tumor cell simultaneously and trigger tumor cell killing; (c) A personalized composition of
minicircles encoding mAbs and BsAbs (i.e., the eAb-vectors) as determined by reference to the patient’s cancer epitope-tree (Fig. 2a) are used to
transfect T cells, which express mAbs and BsAbs in vivo to kill tumor cells via ADCC or to retarget the resting T cell to kill the tumor cell
selectively
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immunodeficiency virus (SIV), which is the counterpart of
human HIV. This resulted in CD8? T cell responses to a
wide range of SIV epitopes presented by both MHC-I and
MHC-II, covering 66 % of the viral protein, which is
threefold greater than that achieved by conventional
vaccination. Importantly, these unconventional CTL re-
sponses cleared the SIV infection, which was resistant to
the conventional vaccine-induced MHC-1-restricted CD8?
T cells [42]. Interestingly, it has also been demonstrated
that the anti-melanoma effects of anti-CTLA-4 were
largely mediated by broadening of the T cell repertoire
[69]. These findings are important because they suggest
that the immune system may be more plastic than pre-
viously thought and that SI may allow exploitation of a
far greater number of cancer- and pathogen-specific
peptide epitopes than those targeted by natural T cells. A
complete understanding of the technology to exploit this
class of antigens may lead to more powerful im-
munotherapy [7, 70].
In summary, SI represents an effective strategy to
overcome the obstacles faced by current immunotherapies
and therapeutic vaccination and to elevate the treatment of
cancers and infectious diseases to a new level of efficacy.
5 DNA vector-based SI
SI can be administered in different ways. A combination of
engineered antibodies (eAbs) and CARTs, for example, can
be used to generate the same set of effector eAbs and T cell
clones as those induced by vaccination. Alternatively, eAbs
alone will also achieve this by using mAbs to mimic
neutralizing Abs and BsAbs to generate effector T cells
(Supporting information Box 2).
The present perspectives propose another solution, that
is, to produce both types of eAbs using optimized non-viral
DNA vectors, minicircles, either ex vivo or in vivo





























































Fig. 2 Synthetic immunity and the cancer epitope-tree. (a) Epitope-tree of a cancer. In this model, the tumor comprises six cell lineages (P1–6)
with five driver mutations (M1–4, M6) and six tumor-specific epitopes (E1–6). Each driver mutation starts a new cell lineage with an additional
growth advantage. A new cell lineage, for example M1E2/P6, can also start with the loss of a driver mutation. Consistent with the high ratio of
passenger to driver mutations, which can be as high as 2,000:1, most of the mutated antigens are derived from passenger mutations and only a
few from driver mutations [31, 44, 45]; therefore, the two biomarkers are not necessarily linked. E, epitope; M, driver mutation; N, normal cell;
Circle, cell lineage; Triangle, epitope; the number inside indicates the sequential number of either mutation (circle) or epitope (triangle). (b) The
four steps of the SI strategy: (1) construct a cancer epitope library from cancer mutation databases; (2) translate this into an eAb library; (3)
construct a library of minicircles encoding the eAbs; (4) use the patient’s cancer sample to determine a patient-specific epitope-tree and, with
reference to this information, select a personalized minicircle set. (c) Deliver the minicircles via ex vivo methods (e.g., PBMC) or in vivo to
express the mAb and BsAbs that mediate the destruction of the targeted cancer or virus-loaded cells
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almost solely the gene expression cassette and are gener-
ated by eliminating the bacterial backbone DNA elements
from standard plasmids [71]. Plasmid backbone DNA is
associated with multiple detrimental effects, such as gene
silencing and the induction of inflammatory responses to
unmethylated CpG motifs. In the absence of plasmid
backbone DNA, minicircles express high levels of gene
products both in vitro and in vivo [73]. Currently, there are
multiple technologies capable of producing high-quality
minicircles with ease [71–73, 75]; consequently, minicir-
cles are widely used by researchers in the biomedical
community and are commercially available worldwide.
Compared to antibody-based SI, minicircles have sev-
eral advantages: (1) it has a huge cost advantage in that
minicircle production, purification, storage and trans-
portation incur only a minor fraction of the costs associated
with the use of antibodies; (2) technically, it will be easier
to generate a library comprising thousands of minicircles
encoding the whole spectrum of anticancer eAbs; (3) for
the same reason, it will be easier to scale-up minicircle
production to meet the demands of the huge patient
populations, even at the level of millions. As such, mini-
circle-based SI has the potential to be available to all pa-
tients worldwide.
Other advantages of minicircle-based SI include its
safety and flexibility. Many US FDA-approved non-viral
DNA vectors are already available to the market, con-
firming the safety of minicircles [76]. In addition to the
expression of eAbs, minicircles can be used to provide
more functions of SI; for example, through expression of
short hairpin RNA (shRNA) to block the pathways leading
to T cell apoptosis and anergy, it will be possible to gen-
erate longer-lived and unsuppressible T cell populations
[77].
Although non-viral DNA vectors have many advantages
compared to viral vectors, including safety and cost, the
problem of delivery has prevented their widespread use.
However, the breakdown of this barrier has begun in the
form of the emergence of technologies for the transfection
of cells with nucleic acids both in vitro [74] and in vivo
[78, 79] that are being evaluated in clinical trials. Although
B lymphocytes are the sole cell type capable of antibody
production, the feasibility of ectopic production by other
cell types has already been tested [80]. In addition to
PBMC or derived products such as dendritic cell/cytokine-
induced killer cell (DC-CIK) for ex vivo applications,
many other cell types, such as muscle or liver sinusoid
endothelial cells, have the potential to mediate the ex-
pression of eAbs by minicircles. Furthermore, the use of
cell types with different life spans provides a convenient
control to the duration of eAb expression. We have con-
structed a series of minicircles encoding anticancer BsAb
and determined their capacity in mediating cancer cell
killing in vitro and in treating B lymphoma in vivo (un-
published data). Nevertheless, there remain rooms for op-
timization of technology in minicircle DNA delivery,
either ex vivo or in vivo, especially in transfection efficacy,
nanomaterial toxicity and targeting accuracy.
In summary, minicircle-based SI has the potential to be
developed as a safe, effective and affordable im-
munotherapeutic strategy that will play a major role in
curing cancers and infections.
6 Future directions
In terms of mechanistic studies, it is critically important to
catalog all somatic mutations to help identify the altered
signaling pathways involved in the pathogenesis of cancers
[81]. For immunotherapy, however, it is important to cat-
alog all the cancer epitopes and to determine the epitope-
tree mapping cancer clonal antigen architecture (Fig. 2a).
This map will guide the selection of an optimal set of
‘‘trunk or major branch’’ epitopes to ensure that the panel
of eAbs will lead to a cure by killing all the cancer cell
lineages without severe toxicity (Figs. 1c, 2b, c). Con-
ceivably, this systematic approach is an effective way to
reveal the ‘‘Achilles’ heel’’ of cancers and to organize a
powerful and effective attack. Fortunately, epitope-tree
construction will be facilitated by its resemblance to a
phylogenic tree and can be constructed using the exome/
genome sequences of the paired cancer and normal sam-
ples; initial progress in this area has already been made
[81]. Currently, the International Cancer Genome Consor-
tium (ICGC) has recorded almost nine million somatic
mutations (Release 16, June 4, 2014), while The Cancer
Genome Atlas (TCGA) reports more than three million (as
of January 23, 2014) [82]. The total number of cancer
epitopes will be markedly fewer, because only a small
percentage of the mutations in these databases will fall into
the protein encoding regions, and only a fraction of the
mutated proteins will be immunogenic. Furthermore, in
most studies documenting malignant heterogeneity, it has
been shown that the driver mutation genes are present at
the trunk of the tree with few exceptions [2, 44]. Ap-
proximately 140 driver mutations have been identified [2],
although most of the epitopes may come from passenger
mutations [1, 7]. The subsequent step, which involves the
construction of the library of antibodies targeting the mu-
tated epitopes (Fig. 2b), will be more challenging.
Although the technology to develop antibodies targeting B
cell epitopes, which are usually cell surface antigens, is
mature, the high throughput technology required to gen-
erate TCR-like antibodies, which interact with intracellular
antigens presented by MHC systems, is not fully devel-
oped. However, this goal should become achievable once a
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worldwide collaboration is established similar to those that
have led to the success of the human and cancer genome
projects.
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